US pharmaceutical giant Johnson & Johnson's single-dose COVID-19 vaccine gets emergency use approval in India on Saturday. Union Health Minister Mansukh Mandaviya gave this information via tweet. This will be the fourth COVID-19 vaccine to be available in the country. India is currently administering three vaccines to its citizens – Serum Institute's Covishield (Oxford-AstraZeneca), Bharat Biotech's Covaxin and Dr. Reddy's Sputnik V (Russia Vaccine).
Meanwhile, Mandaviya tweeted, "India expands its vaccine basket! Johnson and Johnson's single-dose COVID-19 vaccine given approval for Emergency Use in India. Now India has 5 EUA vaccines. This will further boost our nation's collective fight against,
Meanwhile, a Johnson & Johnson India spokesperson wrote on Twitter, " We are pleased to announce that on 7th August 2021, the Government of India issued Emergency Use Authorization (EUA) for the Johnson & Johnson COVID-19 single-dose vaccine in India, to prevent COVID in individuals 18 years of age and older."
India has crossed a milestone of administering 50 crore vaccine doses under the nationwide inoculation drive. With over 49.55 lakh vaccinations in the last 24 hours, India has so far administered over 50.1 crore doses. Meanwhile, the approval of the vaccine of J&J's vaccine is based on the efficacy and security data of the 3rd phase trials. According to company, its single-shot vaccine is 85 percent effective in preventing serious illness in all areas. And reduces the hospitalizations related to Covid-19.
On the other hand, Johnson & Johnson's COVID-19 has showed positive results in South Africa, the co-head of a trial, Glenda Gray, told reporters on Friday. Giving information, South African official Gray said that, as a research, about 4,77,234 health workers of the country have been vaccinated with J&J for the month of February.
Like and Follow us on :
